Original Article
The Effectiveness of Vaccination against Influenza in Healthy, Working Adults
N Engl J Med 1995; 333:889-893October 5, 1995
- Abstract
Background
Although influenza causes substantial morbidity and mortality in all age groups, current recommendations emphasize annual immunization for people at high risk for complications of influenza. We conducted a double-blind, placebo-controlled trial of vaccination against influenza in healthy, working adults.
Methods
In the fall of 1994, we recruited working adults from 18 to 64 years of age from in and around the Minneapolis–St. Paul area and randomly assigned them to receive either influenza vaccine or placebo injections. The primary study outcomes included upper respiratory illnesses, absenteeism from work because of upper respiratory illnesses, and visits to physicians' offices for upper respiratory illnesses. The economic benefits of vaccination were analyzed by estimating the direct and indirect costs associated with immunization and with upper respiratory illnesses.
Results
We enrolled a total of 849 subjects. Base-line characteristics were similar in the two groups. During the follow-up period, consisting of the 1994–1995 influenza season (December 1, 1994, through March 31, 1995), those who received the vaccine reported 25 percent fewer episodes of upper respiratory illness than those who received the placebo (105 vs. 140 episodes per 100 subjects, P<0.001), 43 percent fewer days of sick leave from work due to upper respiratory illness (70 vs. 122 days per 100 subjects, P = 0.001), and 44 percent fewer visits to physicians' offices for upper respiratory illnesses (31 vs. 55 visits per 100 subjects, P = 0.004). The cost savings were estimated to be $46.85 per person vaccinated.
Conclusions
Vaccination against influenza has substantial health-related and economic benefits for healthy, working adults.
Media in This Article
Table 1
Base-Line Characteristics of the Study Subjects.Table 2
Side Effects Associated with Vaccination.Article Activity
- Article
Although most deaths from influenza occur among elderly people, all age groups are affected by this illness. Annual attack rates average 10 to 20 percent and are higher during severe epidemics.1 Symptoms include the abrupt onset of fever, myalgia, sore throat, nonproductive cough, headache, and malaise. Influenza is sometimes associated with malaise persisting for several weeks and often results in restriction of activity.2 Influenza accounts for millions of days lost from work each year.3
The current recommendations of the Advisory Committee on Immunization Practices target persons at increased risk for complications of influenza for annual immunization, although all people who wish to avoid illness are encouraged to consider vaccination.4 We undertook this trial to clarify the benefits of immunization in a population not at high risk for complications. The effects of vaccination on the frequency of upper respiratory illness, sick leave from work, and use of health care services were assessed in healthy, working adults.
Methods
Subjects
Subjects were recruited from the Minneapolis–St. Paul area through advertisements at work sites and in local newspapers and through recruitment sessions at shopping malls. People were eligible if they were 18 to 64 years old, were employed full-time, and had no medical conditions, such as chronic cardiopulmonary disease, diabetes mellitus, or other serious medical conditions, that would place them at high risk for complications of influenza. The criteria for exclusion were a history of immediate hypersensitivity reactions to eggs (because the vaccine may contain small amounts of residual egg protein), thimerosal (a preservative in the vaccine), or previous vaccination against influenza, and pregnancy or planned pregnancy within three months. Informed consent was obtained from all participants. The study was approved by the Human Studies Committee of the Minneapolis Veterans Affairs Medical Center.
Study Design and Data Collection
The study was a randomized, double-blind, placebo-controlled trial. Subjects received injections of vaccine (trivalent subvirion influenza vaccine containing 15 μg of antigen from the component strains A/Texas/36/91, A/Shangdong/9/93, and B/Panama/45/90; Fluzone, Connaught Laboratories, Swiftwater, Pa.) or placebo (vaccine diluent) according to a computer-generated randomization schedule. Ten-unit blocks were used to ensure balanced allocation of subjects to the two groups. Accountability logs in which investigators documented subjects' group assignments were completed to ensure adherence to the randomization schedule. Vaccine and placebo were available in preloaded syringes that were identical in appearance and labeled only with the study code. Blinding was maintained until all study data were collected.
Base-line data on demographic and health-related characteristics were collected by means of a questionnaire administered at the time of enrollment. Follow-up data were obtained through structured telephone interviews. Most telephone surveys were conducted with a computerized, interactive-response telecommunication system (Posit, Health Outcomes Technologies, Doylestown, Pa.). Subjects who required assistance were interviewed by an operator. Five interviews were completed during the follow-up period. The first call was initiated 7 to 14 days after the study injection to collect information on side effects during the week after the injection, and the second through fifth calls were made during January, February, March, and April to identify occurrences of upper respiratory illness, use of sick leave, and visits to physicians' offices in the preceding month. Subjects were also encouraged to record information about these outcomes in “illness logs” and were asked to refer to the logs during their follow-up interviews. During the final interview, subjects were also asked whether they had received an influenza vaccination in addition to the study injection at any time during the study and which study injection they thought they had received.
Study Outcomes and Statistical Analysis
An upper respiratory illness was defined as a sore throat associated with either a fever or a cough that lasted at least 24 hours. On the basis of previous experience with influenza seasons in Minnesota, the follow-up period was defined as December 1, 1994, through March 31, 1995 (the influenza season). The primary outcomes were the totals during four months for episodes of upper respiratory illness, days of work lost because of respiratory illness, and visits to physicians' offices for respiratory illness. Secondary outcomes included the proportion of subjects with any upper respiratory illness, days of respiratory illness, days of work lost because of all illnesses, and estimates of the economic benefits associated with vaccination. Information was also collected on side effects during the week after the study injection.
Bivariate analyses to compare vaccine and placebo recipients included chi-square tests for categorical variables and Student's t-tests for continuous variables. The kappa statistic was used to assess the adequacy and maintenance of blinding.5 The effectiveness of the vaccine was calculated as follows: [(rate of the outcome variable in placebo recipients - rate in vaccine recipients)/rate in placebo recipients] × 100 percent. All statistical tests were performed with SPSS 6.1 for Windows software (SPSS, Chicago).
Estimates of the economic benefits of vaccination were based on the primary study outcomes of sick leave and visits to physicians' offices related to respiratory illness. Costs were calculated from the social perspective as combined direct and indirect costs, as follows6: net costs = direct costs + indirect costs; direct costs = costs of vac-cination + costs of medical care for side effects - costs of medical care for disease averted; indirect costs = costs of work time lost for vaccination + costs of work loss due to side effects - costs of work loss averted.
The numbers of visits to physicians' offices and days of work lost that were avoided because of vaccination were taken from the point estimates for the primary study outcomes. A vaccination was estimated to take 30 minutes of work time and cost $10, on the basis of a survey of public and work-site immunization programs (Nichol KL: unpublished data). The estimate of two days of work lost per 100 vaccinations because of side effects of the vaccine was based on the observed, though statistically nonsignificant, differences between vaccine and placebo recipients during the week after the study injection. We estimated that half the people with side effects would see a physician. Work-loss costs were estimated at $93.40 per day, based on the 1994 median weekly earnings of full-time U.S. workers.7 The cost for a visit to a physician's office was estimated to be $69.51, on the basis of the mean fee for a visit to a physician's office for an established patient in the 1994 American Medical Association Socioeconomic Monitoring System Core Survey,8 a list of diagnostic tests and medications associated with visits to physicians for upper respiratory illnesses from the 1992 National Ambulatory Medical Care Survey of the National Center for Health Statistics, payments to physicians for diagnostic tests from the 1993 Physician Payment Review Commission Multipayer Database, and the costs of generic medications for the treatment of upper respiratory illnesses in a survey of three local branches of national franchise pharmacies (Nichol KL: unpublished data). All costs were adjusted to 1994 dollars with use of the Consumer Price Index. More detailed explanations of these estimates are available elsewhere (NAPS).
Sample-size calculations were based on the expected proportions of subjects with respiratory illnesses. For an event rate of 50 percent in the placebo group with 30 percent of these events being due to influenza (two-sided alpha, 0.05; beta, 0.20), at least 410 subjects per group were needed to enable us to detect differences, assuming a vaccine efficacy of 70 percent. Sample-size calculations were performed with Power software (Epicenter Software, Pasadena, Calif.).
Results
A total of 849 subjects were enrolled between October 10 and November 30, 1994. The characteristics of the subjects according to treatment assignment are shown in Table 1Table 1
Base-Line Characteristics of the Study Subjects.. Randomization resulted in an even distribution of all base-line measures, including characteristics that might be independently related to the study outcomes, such as health status, number of children in the household, smoking status, and sick leave during the past six months.After enrollment, 3 subjects were dropped from the study because of incorrect addresses and telephone numbers, leaving 424 placebo and 422 vaccine recipients. Follow-up interviews to ascertain side effects were completed for 841 subjects (99 percent). There were no significant differences between vaccine and placebo recipients with regard to specific systemic symptoms, although vaccine recipients were more likely to report local symptoms (Table 2Table 2
Side Effects Associated with Vaccination.). The mean number of days of sick leave during the week following the injection was 4.5 per 100 for the placebo recipients and 6.5 per 100 for the vaccine recipients (P = 0.34).After the interview focusing on side effects, five additional subjects were withdrawn. The reasons included a refusal to continue with the study (two subjects in the vaccine group) and incorrect addresses or telephone numbers (two subjects in the placebo group and one in the vaccine group). Complete follow-up data were obtained for 416 of 422 placebo recipients (99 percent) and 409 of 419 vaccine recipients (98 percent; P = 0.44).
During the study period, 69 percent of the placebo recipients and 61 percent of the vaccine recipients had at least one upper respiratory illness (P = 0.018). Cumulative rates of respiratory illness, sick leave, and visits to physicians' offices for respiratory illnesses and associated rates of vaccine effectiveness are summarized in Table 3Table 3
Health-Related Benefits Associated with Vaccination.. For each outcome, vaccination was associated with significantly fewer events, with the greatest reductions in the more severe outcomes: days of work lost and visits to physicians' offices.The original treatment assignments were well maintained throughout the study. Only one person in the placebo group (0.2 percent) and two in the vaccine group (0.5 percent) received influenza vaccine from another source. Blinding was also well maintained. When asked during the final interview which type of injection they thought they had received, only 60.3 percent of the placebo recipients and 54.3 percent of the vaccine recipients correctly identified their injection, with an overall rate of agreement of 57 percent. This correlated with a kappa of 0.15, indicating agreement only slightly better than would have resulted from chance alone.
The results of the economic analysis are shown in Table 4Table 4
Economic Benefits Associated with Vaccination.. On the basis of the outcomes observed in the trial, direct savings in medical costs were estimated to be $5.99 per person vaccinated ($599 per 100 persons), and indirect cost savings were estimated to be $40.86 per person vaccinated ($4,086 per 100 persons). Combined cost savings were estimated to be $46.85 per person vaccinated ($4,685 per 100 persons).Discussion
The results of this placebo-controlled trial show the benefits that vaccination against influenza offers for healthy, working adults. Immunization decreased the frequency of upper respiratory illnesses by 25 percent, absenteeism from work due to upper respiratory illness by 43 percent, absenteeism due to all illnesses by 36 percent, and visits to physicians' offices for upper respiratory illness by 44 percent. On the basis of the observed decreases in sick leave and visits to physicians for upper respiratory illness, we estimate that vaccination was associated with cost savings of $46.85 per person vaccinated.
Previous studies of the clinical effectiveness of the influenza vaccine in working adults have had varying results. Trials in the 1950s and 1960s in the United Kingdom,9-11 United States,12 and Australia,13 using early monovalent or bivalent formulations of the vaccine, demonstrated a reduction in absenteeism during some but not all influenza seasons. The years in which the vaccine was found to be ineffective were generally those in which there was a poor match between the virus strains in the vaccine and circulating strains. A five-year study in the early 1970s among postal workers in the United Kingdom also suggested benefit.14 The findings of that study, however, are unreliable because of base-line differences in absenteeism between the intervention and control groups. More recent trials in the United States have confirmed the efficacy of the vaccine among healthy adults, as indicated by the frequency of laboratory-confirmed infection.15,16 In one study, rates of clinical illness were also decreased,16 but absenteeism from work was not evaluated. Another recent trial that assessed rates of clinical illness and absenteeism failed to demonstrate a benefit.17 That study had a small sample, however. Furthermore, during the 1985–1986 study year, there was a poor match between the vaccine strains and circulating viruses.
The present study extends these observations. Our trial had a sample of adequate size; the study year was characterized by an excellent match between the strains in the vaccine and the predominant circulating virus strains, as has been the case for seven of the past nine years (Cox N, Centers for Disease Control and Prevention: personal communication); and we evaluated a broad range of outcomes including clinical illness, absenteeism from work, use of health care services, and economic benefits.
The benefits observed in this study probably represent a low-to-intermediate estimate of the benefits that might be seen in other years. Influenza activity was at low-to-moderate levels in Minnesota in 1994–1995.18 During seasons with higher levels of activity, such as years when there are severe epidemics, the benefits of vaccination would undoubtedly be greater.
Our study was not designed to detect differences between vaccine and placebo recipients with regard to serious complications of influenza, including hospitalization and death. Influenza epidemics are, however, associated with increased rates of hospitalization for acute respiratory disease in all age groups.19-21 Furthermore, influenza — together with pneumonia — accounts for 6000 to 7000 deaths each year among persons 18 to 64 years of age.22,23 A substantial proportion of these deaths probably represent mortality associated with influenza epidemics.21 Vaccination against influenza markedly decreases the numbers of hospitalizations and deaths due to complications of influenza among the elderly.24-27 It is probable that vaccination is of similar benefit in younger persons.
In our study, vaccination was associated not only with a reduction in days of work lost because of upper respiratory illness but also with a reduction in absenteeism due to all illnesses. Upper respiratory infections accounted for approximately 65 percent of sick-leave days during the study period. Because only half the people with influenza have classic symptoms,1 it is likely that some subjects with influenza did not have upper respiratory symptoms. This would have resulted in a misclassification of their illnesses into a non–upper-respiratory category. Episodes of influenza may also have predisposed subjects to secondary illnesses.
Vaccination of the elderly against influenza clearly saves money.3,26-28 Analyses of the influenza vaccine in healthy, younger adults also suggest that vaccination is cost effective and possibly cost saving.3,29-31 Our estimates of direct and indirect cost savings corroborate these findings and indicate that the economic benefits of vaccinating working adults may be greater than previously estimated. Our figures may underestimate the actual savings associated with vaccination in this population for several reasons. We did not, for example, include in our analysis savings associated with decreases in nonrespiratory illnesses or decreases in the rates of hospitalization and death due to influenza and its complications. The economic benefits for a particular population depend, of course, on the actual costs of illness in that population, the type and severity of influenza, the clinical attack rate, and the effectiveness of the vaccine during the season in question.
Concern about side effects is a barrier to immunization. Two recent trials have shown that the vaccination of elderly people against influenza is not associated with higher rates of systemic side effects than placebo injections.32,33 In our study we observed virtually identical results among younger, low-risk subjects.
We relied on subjects' own reports as the measure of clinical outcomes in this study. Such reports of sick leave have been shown to be reliable and accurate.34 In our study, we minimized the recall period (and the possibility of recall bias) for subjects by conducting monthly follow-up interviews. Blinding was also well maintained despite the higher rate of local reactions among vaccine recipients. Therefore, the subjects' reports of outcomes should have provided a valid and unbiased estimate of the effects of vaccination in the study.
The group of participants in this study was broadly representative of the general population. Exclusion criteria were kept to a minimum, recruitment was conducted in a variety of settings, and participation was made as convenient as possible. The results of this study should therefore be generalizable to other working adults and have important implications for the 87 million full-time workers in the United States.7
Supported in part by grants from the Blue Cross Blue Shield of Minnesota Foundation and Connaught Laboratories.
NAPS See NAPS document no. 05247 for three pages of supplementary material. To order, contact NAPS c/o Microfiche Publications, 248 Hempstead Tpk., West Hempstead, NY 11552.
We are indebted to the participating employers and the many other people who supported our recruitment efforts for this study.
Source Information
From the Veterans Affairs Medical Center (K.L.N., A.L., M.M., M.H.), Hennepin County Medical Center (K.L.M., R.M.), and the University of Minnesota Medical School (K.L.N., A.L., K.L.M., M.M., R.M., S.M.), Minneapolis; Blue Plus, an affiliate of Blue Cross Blue Shield of Minnesota, Eagan (S.M.); and the American Lung Association of Minnesota, St. Paul (M.D.).
Address reprint requests to Dr. Nichol at the Section of General Internal Medicine (111O), Veterans Affairs Medical Center, One Veterans Dr., Minneapolis, MN 55417.
- References
References
1
LaForce FM ,Nichol KL ,Cox NJ . Influenza: virology, epidemiology, disease, and prevention. Am J Prev Med 1994;10:Suppl:31-44
Web of Science | Medline2
Sullivan KM ,Monto AS ,Longini IM Jr . Estimates of the US health impact of influenza. Am J Public Health 1993;83:1712-1716
CrossRef | Web of Science | Medline3
Riddiough MA ,Sisk JE ,Bell JC . Influenza vaccination: cost-effectiveness and public policy. JAMA 1983;249:3189-3195
CrossRef | Web of Science | Medline4
Prevention and control of influenza: vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994;43:1-13
Medline5
Feinstein AR. Clinical epidemiology: the architecture of clinical research. Philadelphia: W.B. Saunders, 1985:186.
6
Centers for Disease Control and Prevention. A practical guide to prevention effectiveness: decision and economic analyses. Atlanta: Centers for Disease Control and Prevention, 1994:57-68.
7
Green GP, Becker EH, eds. Employment and earnings. Vol. 42. No. 1. Washington, D.C.: Government Printing Office, 1995:207.
8
Gonzalez ML, ed. Socioeconomic characteristics of medical practice 1995. Chicago: American Medical Association, 1995:98.
9
Clinical trials of influenza vaccine: a progress report to the Medical Research Council by its Committee on Clinical Trials of Influenza Vaccine. BMJ 1953;2:1173-1177
CrossRef | Web of Science10
Clinical trials of influenza vaccine: third progress report to the Medical Research Council by its Committee on Clinical Trials of Influenza Vaccine. BMJ 1957;2:1-7
CrossRef | Web of Science11
Clinical trials of oil-adjuvant influenza vaccines, 1960-3: report to the Medical Research Council by its Committee on Influenza and Other Respiratory Virus Vaccines. BMJ 1964;2:267-271
CrossRef | Web of Science12
Edmondson WP ,Rothenberg R ,White PW ,Gwaltney JM Jr . A comparison of subcutaneous, nasal, and combined influenza vaccination. II. Protection against natural challenge. Am J Epidemiol 1971;93:480-486
Web of Science | Medline13
Edmondson KW ,Graham DSM ,Warburton MF . A clinical trial of influenza vaccine in Canberra. Med J Aust 1970;2:6-13
Web of Science | Medline14
Smith JW ,Pollard R . Vaccination against influenza: a five-year study in the post office. J Hyg (Lond) 1979;83:157-170
CrossRef | Web of Science | Medline15
Keitel WA ,Cate TR ,Couch RB . Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1988;127:353-364
Web of Science | Medline16
Edwards KM ,Dupont WD ,Westrich MK ,Plummer WD Jr ,Palmer PS ,Wright PF . A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169:68-76
CrossRef | Web of Science | Medline17
Weingarten S ,Staniloff H ,Ault M ,Miles P ,Bamberger M ,Meyer RD . Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial. J Gen Intern Med 1988;3:32-37
CrossRef | Web of Science | Medline18
Minnesota Department of Health. Annual summary of communicable diseases reported to the Minnesota Department of Health, 1994. Vol. 23. Disease Control Newsletter. June/July 1995:36.
19
Glezen WP . Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982;4:25-44
Web of Science | Medline20
Perrotta DM ,Decker M ,Glezen WP . Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 1985;122:468-476
Web of Science | Medline21
Lui KJ ,Kendal AP . Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77:712-716
CrossRef | Web of Science | Medline22
Kochanek KD, Hudson BL. Advance report of final mortality statistics, 1992. Monthly vital statistics report. Vol. 43. No. 6. Suppl. Hyattsville, Md.: National Center for Health Statistics, 1995.
23
National Center for Health Statistics. Vital statistics of the United States. Vol. II. Mortality. Part A, 1979–1992. Compendium. Washington, D.C.: Public Health Service, 1995.
24
Foster DA ,Talsma A ,Furumoto-Dawson A , et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992;136:296-307
Web of Science | Medline25
Fedson DS ,Wajda A ,Nicol JP ,Hammond GW ,Kaiser DL ,Roos LL . Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993;270:1956-1961[Erratum, JAMA 1994;271:1578.]
CrossRef | Web of Science | Medline26
Mullooly JP ,Bennett MD ,Hornbrook MC , et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994;121:947-952
Web of Science | Medline27
Nichol KL ,Margolis KL ,Wuorenma J ,Von Sternberg T . The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784
Full Text | Web of Science | Medline28
Final results: Medicare influenza vaccine demonstration -- selected states, 1988-1992. MMWR Morb Mortal Wkly Rep 1993;42:601-604
Medline29
Schoenbaum SC ,McNeil BJ ,Kavet J . The swine-influenza decision. N Engl J Med 1976;295:759-765
Full Text | Web of Science | Medline30
Schoenbaum SC . Economic impact of influenza: the individual's perspective. Am J Med 1987;82:Suppl 6A:26-30
CrossRef | Web of Science | Medline31
Yassi A ,Kettner J ,Hammond G ,Cheang M ,McGill M . Effectiveness and cost-benefit of an influenza vaccination program for health care workers. Can J Infect Dis 1991;2:101-10832
Margolis KL ,Nichol KL ,Poland GA ,Pluhar RE . Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. JAMA 1990;246:1139-1141
CrossRef | Web of Science33
Govaert TM ,Dinant GJ ,Aretz K ,Masurel N ,Sprenger MJ ,Knottnerus JA . Adverse reactions to influenza vaccine in elderly people: a randomised double blind placebo controlled trial. BMJ 1993;307:988-990
CrossRef | Web of Science | Medline34
Revicki DA ,Irwin D ,Reblando J ,Simon GE . The accuracy of self-reported disability days. Med Care 1994;32:401-404
CrossRef | Web of Science | Medline
- Citing Articles (216)
Citing Articles
1
H. J. Ehrlich, J. Singer, G. Berezuk, S. Fritsch, G. Aichinger, M. K. Hart, W. El-Amin, D. Portsmouth, O. Kistner, P. N. Barrett. (2012) A Cell Culture-Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals. Clinical Infectious Diseases
CrossRef2
Roman Prymula, Gaye Usluer, Serdar Altinel, Radka Sichova, Françoise Weber. (2012) Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey. Advances in Therapy
CrossRef3
Justin Gatwood, Martin I. Meltzer, Mark Messonnier, Ismael R. Ortega-Sanchez, Rajesh Balkrishnan, Lisa A. Prosser. (2012) Seasonal Influenza Vaccination of Healthy Working-Age Adults. Drugs 72:1, 35-48
CrossRef4
Patricia A. Murphy, Sharon G. Frazee, Jack P. Cantlin, Ed Cohen, Jay R. Rosan, Devonee E. Harshburger. (2012) Pharmacy provision of influenza vaccinations in medically underserved communities. Journal of the American Pharmacists Association 52:1, 67-70
CrossRef5
A.N.M. Ng, C.K.Y. Lai. (2011) Effectiveness of seasonal influenza vaccination in healthcare workers: a systematic review. Journal of Hospital Infection 79:4, 279-286
CrossRef6
Gerjo Kok, Gerrit A. van Essen, Sabine Wicker, Anna Llupià, Guillermo Mena, Raquel Correia, Robert A.C. Ruiter. (2011) Planning for influenza vaccination in health care workers: An Intervention Mapping approach. Vaccine 29:47, 8512-8519
CrossRef7
Zoltan Vajo. (2011) The seasonal influenza vaccine Agriflu ®. Expert Review of Vaccines 10:11, 1513-1517
CrossRef8
Jürgen Maurer, Katherine M. Harris, Andrew M. Parker. (2011) Who knew? Awareness of being recommended for influenza vaccination among US adults. Influenza and Other Respiratory Virusesno-no
CrossRef9
Stephan Ludwig. (2011) Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biological Chemistry 392:10, 837-847
CrossRef10
Marie A. Perio, Douglas M. Wiegand, Stefanie M. Evans. (2011) Low Influenza Vaccination Rates Among Child Care Workers in the United States: Assessing Knowledge, Attitudes, and Behaviors. Journal of Community Health
CrossRef11
Mark H Yudin. (2011) Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy. Expert Review of Respiratory Medicine 5:4, 495-501
CrossRef12
Michelle S. Glaser, Sydney Chui, Mayris P. Webber, Jackson Gustave, Roy Lee, Mary T. McLaughlin, Viola Ortiz, David Prezant, Kerry Kelly. (2011) Predictors of acceptance of H1N1 influenza vaccination by FDNY firefighters and EMS workers. Vaccine 29:34, 5675-5680
CrossRef13
Richard Strugnell, Fred Zepp, Anthony Cunningham, Terapong Tantawichien. (2011) Vaccine antigens. Perspectives in Vaccinology 1:1, 61-88
CrossRef14
Eliza LY Wong, Samuel YS Wong, Nelson Lee, Annie Cheung, Sian Griffiths. (2011) Healthcare workers’ duty concerns of working in the isolation ward during the novel H1N1 pandemic. Journal of Clinical Nursingno-no
CrossRef15
Laurie Jo Johansen, Thomas Stenvig, Howard Wey. (2011) The Decision to Receive Influenza Vaccination Among Nurses in North and South Dakota. Public Health Nursingno-no
CrossRef16
J. G. Petrie, S. E. Ohmit, E. Johnson, R. T. Cross, A. S. Monto. (2011) Efficacy Studies of Influenza Vaccines: Effect of End Points Used and Characteristics of Vaccine Failures. Journal of Infectious Diseases 203:9, 1309-1315
CrossRef17
Michael W. Hubble, Tracy L. Zontek, Michael E. Richards. (2011) Predictors of Influenza Vaccination among Emergency Medical Services Personnel. Prehospital Emergency Care 15:2, 175-183
CrossRef18
Bradford D Gessner, Nahoko Shindo, Sylvie Briand. (2011) Seasonal influenza epidemiology in sub-Saharan Africa: a systematic review. The Lancet Infectious Diseases 11:3, 223-235
CrossRef19
Antoine Nougairède, Rémi N. Charrel, Didier Raoult. (2011) Models cannot predict future outbreaks: A/H1N1 virus, the paradigm. European Journal of Epidemiology 26:3, 183-186
CrossRef20
O. Yu Atʼkov, A.V. Azarov, D.A. Zhukov, N. Nicoloyannis, L. Durand. (2011) Influenza Vaccination in Healthy Working Adults in Russia. Applied Health Economics and Health Policy 9:2, 89-99
CrossRef21
Matthew Groenewold, Sherry Baron, SangWoo Tak, Norma Allred. (2011) Influenza Vaccination Coverage Among US Nursing Home Nursing Assistants: The Role of Working Conditions. Journal of the American Medical Directors Association
CrossRef22
Jan Gralton, Mary-Louise McLaws. (2011) Using evidence-based medicine to protect healthcare workers from pandemic influenza: Is it possible?. Critical Care Medicine 39:1, 170-178
CrossRef23
Gasmelseed Y Ahmed, Hanan H Balkhy, Saleh Bafaqeer, Badr Al-Jasir, Abdulhakeem Althaqafi. (2011) Acceptance and Adverse Effects of H1N1 Vaccinations Among a Cohort of National Guard Health Care Workers during the 2009 Hajj Season. BMC Research Notes 4:1, 61
CrossRef24
Kenzo Takahashi, Yasushi Ohkusa, Jong-Young Kim. (2011) The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study. BMC Health Services Research 11:1, 254
CrossRef25
Chyongchiou J. Lin, Mary Patricia Nowalk, Seth L. Toback, Matthew D. Rousculp, Mahlon Raymund, Christopher S. Ambrose, Richard K. Zimmerman. (2010) Importance of vaccination habit and vaccine choice on influenza vaccination among healthy working adults. Vaccine 28:48, 7706-7712
CrossRef26
Bruce Y. Lee, Rachel R. Bailey, Ann E. Wiringa, Abena Afriyie, Angela R. Wateska, Kenneth J. Smith, Richard K. Zimmerman. (2010) Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine 28:37, 5952-5959
CrossRef27
Tom Jefferson, Carlo Di Pietrantonj, Alessandro Rivetti, Ghada A Bawazeer, Lubna A Al-Ansary, Eliana Ferroni, Tom Jefferson. 2010. Vaccines for preventing influenza in healthy adults. .
CrossRef28
Liisa A. Palmer, Matthew D. Rousculp, Stephen S. Johnston, Parthiv J. Mahadevia, Kristin L. Nichol. (2010) Effect of influenza-like illness and other wintertime respiratory illnesses on worker productivity: The child and household influenza-illness and employee function (CHIEF) study. Vaccine 28:31, 5049-5056
CrossRef29
Jessica N. Kent, C. Suzanne Lea, Xiangming Fang, Lloyd F. Novick, Jo Morgan. (2010) Seasonal Influenza Vaccination Coverage Among Local Health Department Personnel in North Carolina, 2007–2008. American Journal of Preventive Medicine 39:1, 74-77
CrossRef30
H-H. Lin, K-L. Hsu, W. W-C. Ko, Y-C. Yang, Y-W. Chang, M-C. Yu, K-T. Chen. (2010) Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan. Clinical Microbiology and Infection 16:6, 663-670
CrossRef31
Pranita D Tamma, Marc C Steinhoff, Saad B Omer. (2010) Influenza infection and vaccination in pregnant women. Expert Review of Respiratory Medicine 4:3, 321-328
CrossRef32
Alberto J. Caban-Martinez, David J. Lee, Evelyn P. Davila, William G. LeBlanc, Kristopher L. Arheart, Kathryn E. McCollister, Sharon L. Christ, Tainya Clarke, Lora E. Fleming. (2010) Sustained low influenza vaccination rates in US healthcare workers. Preventive Medicine 50:4, 210-212
CrossRef33
Mary Patricia Nowalk, Chyongchiou J. Lin, Seth L. Toback, Matthew D. Rousculp, Charles Eby, Mahlon Raymund, Richard K. Zimmerman. (2010) Improving Influenza Vaccination Rates in the Workplace. American Journal of Preventive Medicine 38:3, 237-246
CrossRef34
Philip Cooley, Bruce Y. Lee, Shawn Brown, James Cajka, Bernadette Chasteen, Laxminarayana Ganapathi, James H. Stark, William D. Wheaton, Diane K. Wagener, Donald S. Burke. (2010) Protecting health care workers: a pandemic simulation based on Allegheny County. Influenza and Other Respiratory Viruses 4:2, 61-72
CrossRef35
Tom Jefferson, Chris Del Mar, Liz Dooley, Eliana Ferroni, Lubna A Al-Ansary, Ghada A Bawazeer, Mieke L van Driel, Sreekumaran Nair, Ruth Foxlee, Alessandro Rivetti. 2010. .
CrossRef36
Tomoko MORIMOTO, Hirofumi ISHIKAWA. (2010) Evaluation of Vaccination Strategies to Suppress a Novel Influenza Pandemic Using an Individual-Based Model. Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene) 65:3, 459-466
CrossRef37
Sally L. Hodder, Debra Chew, Shobha Swaminathan. 2010. Adult Immunization in Women and Men. , 563-582.
CrossRef38
Joost R. Santos, Mark J. Orsi, Erik J. Bond. (2009) Pandemic Recovery Analysis Using the Dynamic Inoperability Input-Output Model. Risk Analysis 29:12, 1743-1758
CrossRef39
Christy M. Tabarani, Joseph B. Domachowske. (2009) Influenza Vaccination of Healthcare Personnel. Pediatric Annals 38:12, 661-666
CrossRef40
Pranita D. Tamma, Kevin A. Ault, Carlos del Rio, Mark C. Steinhoff, Neal A. Halsey, Saad B. Omer. (2009) Safety of influenza vaccination during pregnancy. American Journal of Obstetrics and Gynecology 201:6, 547-552
CrossRef41
Michael G Ison. (2009) Anti-influenza therapy: the emerging challenge of resistance. Therapy 6:6, 883-891
CrossRef42
Yu Tai, Ta-Chung Lee, Hsiao-Ling Chang, Kow-Tong Chen. (2009) Epidemiology and outcomes of hospitalization of influenza in the cancer population in Taiwan. Journal of Cancer Research and Clinical Oncology 135:8, 1061-1066
CrossRef43
S. Ludwig. (2009) Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. Journal of Antimicrobial Chemotherapy 64:1, 1-4
CrossRef44
De-chu C Tang, Jianfeng Zhang, Haroldo Toro, Zhongkai Shi, Kent R Van Kampen. (2009) Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Review of Vaccines 8:4, 469-481
CrossRef45
Wilfred Ndifon, Jonathan Dushoff, Simon A. Levin. (2009) On the use of hemagglutination-inhibition for influenza surveillance: Surveillance data are predictive of influenza vaccine effectiveness. Vaccine 27:18, 2447-2452
CrossRef46
David Liebowitz, Bin Lu. (2009) Making improvements in influenza vaccines: incremental change or transformational evolution?. Future Virology 4:2, 133-141
CrossRef47
Gregory A. Poland. (2009) Valuing Influenza Vaccine: Medical, Economic, and Social Benefits. Clinical Infectious Diseases 48:3, 299-301
CrossRef48
William G. Fernandez, Leslie Oyama, Patricia Mitchell, Erika M. Edwards, Jill St. George, Jacqueline Donovan, James A. Feldman. (2009) Attitudes and Practices Regarding Influenza Vaccination Among Emergency Department Personnel. The Journal of Emergency Medicine 36:2, 201-206
CrossRef49
Edward A. Belongia, Burney A. Kieke, James G. Donahue, Robert T. Greenlee, Amanda Balish, Angie Foust, Stephen Lindstrom, David K. Shay, . (2009) Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 Season. The Journal of Infectious Diseases 199:2, 159-167
CrossRef50
Mi-Jung Kim, Seung-Youn Lee, Kwang-Soo Lee, Aerum Kim, Dongwook Son, Moon-Hyun Chung, Shin-Goo Park, Ji-Hyun Park, Byung-Ik Lee, Jin-Soo Lee. (2009) Influenza Vaccine Coverage Rate and Related Factors on Pregnant Women. Infection and Chemotherapy 41:6, 349
CrossRef51
Nicholas T. Vozoris, M. Diane Lougheed. (2009) Influenza vaccination among Canadians with chronic respiratory disease. Respiratory Medicine 103:1, 50-58
CrossRef52
O. Anikeeva, A. Braunack-Mayer, W. Rogers. (2008) Requiring Influenza Vaccination for Health Care Workers. American Journal of Public Health 99:1, 24-29
CrossRef53
Zoltan Vajo, Lajos Kosa, Istvan Szilvasy, Zsuzsanna Pauliny, Kálmán Bartha, Ildiko Visontay, Mate Jankovics, Agnes Kis, Istvan Jankovics. (2008) Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval - a useful approach to pandemic vaccine development even in less well developed countries?. Influenza and Other Respiratory Viruses 2:6, 221-228
CrossRef54
Robert B. Couch. (2008) Seasonal inactivated influenza virus vaccines. Vaccine 26, D5-D9
CrossRef55
V. Sivaprakasam, J. Douglas, S. Selvaraj, S. MacIntyre, W.F. Carman. (2008) The effectiveness of national influenza vaccination policies for at-risk populations over 5 seasons in a Scottish general practice. Vaccine 26:29-30, 3772-3777
CrossRef56
Catherine WM Ong, Paul Ananth Tambyah. (2008) Update on antivirals and vaccines for seasonal and potential pandemic use. Expert Review of Respiratory Medicine 2:3, 391-402
CrossRef57
Christopher Burrell, Robert Booy, Nicholas Wood, Anne-Marie Egan, David Taverner, Ken Williams, Winston Liauw, Alan Moskwa, Stephanie Pepin-Covatta, Melanie Saville. (2008) Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine. Influenza and Other Respiratory Viruses 2:3, 93-98
CrossRef58
Ronald J. Teufel, William T. Basco, Kit N. Simpson. (2008) Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. Journal of Hospital Medicine 3:2, 134-141
CrossRef59
Pengjun Lu, Carolyn B. Bridges, Gary L. Euler, James A. Singleton. (2008) Influenza vaccination of recommended adult populations, U.S., 1989–2005. Vaccine 26:14, 1786-1793
CrossRef60
Lee Sock Hui, Hesham Rashwan, Mohd Hasni bin Jaafar, Haizal Mohd Hussaini, Datin Ilina Isahak. (2008) Effectiveness of influenza vaccine in preventing influenza-like illness among Faculty of Dentistry staff and students in Universiti Kebangsaan Malaysia. Healthcare Infection 13:1, 4
CrossRef61
Elizabeth R. Bellaard-Smith, Rhonda L. Stuart, Elizabeth E. Gillespie. (2008) Improving influenza vaccination rates in a large health service. Healthcare Infection 13:2, 63
CrossRef62
Lisa A Prosser, Megan A O’Brien, Noelle-Angelique M Molinari, Katherine H Hohman, Kristin L Nichol, Mark L Messonnier, Tracy A Lieu. (2008) Non-Traditional Settings for Influenza Vaccination of Adults. PharmacoEconomics 26:2, 163-178
CrossRef63
Martin Keech, Paul Beardsworth. (2008) The Impact of Influenza on Working Days Lost. PharmacoEconomics 26:11, 911-924
CrossRef64
Florence T Bourgeois, William W Simons, Karen Olson, John S Brownstein, Kenneth D Mandl. (2008) Evaluation of Influenza Prevention in the Workplace Using a Personally Controlled Health Record: Randomized Controlled Trial. Journal of Medical Internet Research 10:1, e5
CrossRef65
Agnes L. F. Chan, Huei-Jen Shie, Yung-Jin Lee, Shun-Jin Lin. (2007) The evaluation of free influenza vaccination in health care workers in a medical center in Taiwan. Pharmacy World & Science 30:1, 39-43
CrossRef66
Sabine Arnoux, Clement Weinberger, Bradford D. Gessner. (2007) Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip – an inactivated split virion influenza vaccine – supports wider vaccine use. Vaccine 25:45, 7720-7731
CrossRef67
Robert B. Belshe, Frances K. Newman, Ken Wilkins, Irene L. Graham, Elizabeth Babusis, Marian Ewell, Sharon E. Frey. (2007) Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25:37-38, 6755-6763
CrossRef68
Elenir B. C. Avritscher, Catherine D. Cooksley, Jane M. Geraci, Benjamin N. Bekele, Scott B. Cantor, Kenneth V. Rolston, Linda S. Elting. (2007) Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer 109:11, 2357-2364
CrossRef69
Vittorio Demicheli, Carlo Di Pietrantonj, Tom Jefferson, Alessandro Rivetti, Daniela Rivetti, Daniela Rivetti. 2007. Vaccines for preventing influenza in healthy adults. .
CrossRef70
Samuel Aballéa, Jeremy Chancellor, Monique Martin, Peter Wutzler, Fabrice Carrat, Roberto Gasparini, Joao Toniolo-Neto, Michael Drummond, Milton Weinstein. (2007) The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model. Value in Health 10:2, 98-116
CrossRef71
Pedro Plans-Rubió. (2007) Prevention and control of influenza in persons with chronic obstructive pulmonary disease. International Journal of COPD 2:1, 41-53
CrossRef72
Mónica Olivares, Maria Paz Díaz-Ropero, Saleta Sierra, Federico Lara-Villoslada, Juristo Fonollá, Mónica Navas, Juan Miguel Rodríguez, Jordi Xaus. (2007) Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition 23:3, 254-260
CrossRef73
Mary Bertin, Michele Scarpelli, Andrew W. Proctor, John Sharp, Ethel Robitson, Todd Donnelly, Claire Young, Steven M. Gordon. (2007) Novel use of the intranet to document health care personnel participation in a mandatory influenza vaccination reporting program. American Journal of Infection Control 35:1, 33-37
CrossRef74
John P. Mullooly, Carolyn B. Bridges, William W. Thompson, Jufu Chen, Eric Weintraub, Lisa A. Jackson, Steve Black, David K. Shay. (2007) Influenza- and RSV-associated hospitalizations among adults. Vaccine 25:5, 846-855
CrossRef75
E. Rizzuto, A.M. Prete, L. Virtuani, M.G. Pompa. (2006) Effectiveness of influenza vaccination: A survey within the Italian Ministry of Health personnel. Vaccine 24:44-46, 6612-6614
CrossRef76
Benjamin Schwartz, Alan Hinman, Jon Abramson, Raymond A. Strikas, Norma Allred, Timothy Uyeki, Walter Orenstein. (2006) Universal Influenza Vaccination in the United States: Are We Ready? Report of a Meeting. The Journal of Infectious Diseases 194:s2, S147-S154
CrossRef77
Takashi Kato, Akiko Kiire, Hazime Yamagata, Hisashi Yamanaka, Naoyuki Kamatani. (2006) Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections. Modern Rheumatology 16:5, 327-329
CrossRef78
Christoph Wenisch. (2006) Akute Exazerbation bei COPD. Wiener klinische Wochenschrift Education 1:2, 85-91
CrossRef79
W.K. Bryant, D.C. Ompad, S. Sisco, S. Blaney, K. Glidden, E. Phillips, D. Vlahov, S. Galea. (2006) Determinants of influenza vaccination in hard-to-reach urban populations. Preventive Medicine 43:1, 60-70
CrossRef80
Paola Sebastiani, Kenneth D. Mandl, Peter Szolovits, Isaac S. Kohane, Marco F. Ramoni. (2006) A Bayesian dynamic model for influenza surveillance. Statistics in Medicine 25:11, 1803-1816
CrossRef81
Scott Roberts, Lisa M. Hollier, Jeanne Sheffield, Vanessa Laibl, George D. Wendel. (2006) Cost-Effectiveness of Universal Influenza Vaccination in a Pregnant Population. Obstetrics & Gynecology 107:6, 1323-1329
CrossRef82
Jeffrey C. Hageman, Timothy M. Uyeki, John S. Francis, Daniel B. Jernigan, J. Gary Wheeler, Carolyn B. Bridges, Stephen J. Barenkamp, Dawn M. Sievert, Arjun Srinivasan, Meg C. Doherty, Linda K. McDougal, George E. Killgore, Uri A. Lopatin, Rebecca Coffman, J. Kathryn MacDonald, Sigrid K. McAllister, Gregory E. Fosheim, Jean B. Patel, L. Clifford McDonald. (2006) Severe Community-acquired Pneumonia Due to Staphylococcus aureus , 2003–04 Influenza Season. Emerging Infectious Diseases 12:6, 894-899
CrossRef83
Vishal Gupta, David J. Earl, Michael W. Deem. (2006) Quantifying influenza vaccine efficacy and antigenic distance. Vaccine 24:18, 3881-3888
CrossRef84
H. Backer. (2006) Counterpoint: In Favor of Mandatory Influenza Vaccine for All Health Care Workers. Clinical Infectious Diseases 42:8, 1144-1147
CrossRef85
M. Finch. (2006) Point: Mandatory Influenza Vaccination for All Heath Care Workers? Seven Reasons to Say "No". Clinical Infectious Diseases 42:8, 1141-1143
CrossRef86
Giorgio L Colombo, Antonio Ferro, Marta Vinci, Maria Zordan, Giulio Serra. (2006) Cost-benefit analysis of influenza vaccination in a public healthcare unit. Therapeutics and Clinical Risk Management 2:2, 219-226
CrossRef87
Maarten J Postma, Rob PM Baltussen, Abraham M Palache, Jan C Wilschut. (2006) Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 6:2, 215-227
CrossRef88
Michael Mair, Robert W. Grow, Julie Samia Mair, Lewis J. Radonovich. (2006) Universal Influenza Vaccination: The Time to Act Is Now. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 4:1, 20-40
CrossRef89
Danielle B. Scheurer. (2006) Improving Inpatient Vaccinations: A Long Road Ahead. Southern Medical Journal 99:3, 203-204
CrossRef90
Michael Mair, Robert W. Grow, Julie Samia Mair, Lewis J. Radonovich. (2006) Universal Influenza Vaccination: The Time to Act Is Now. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 0:0, 060224114020001
CrossRef91
D.A. Turner, A.J. Wailoo, N.J. Cooper, A.J. Sutton, K.R. Abrams, K.G. Nicholson. (2006) The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine 24:7, 1035-1043
CrossRef92
Phillippa Poole, Emme E Chacko, Richard Wood-Baker, Christopher J Cates, Phillippa Poole. 2006. Influenza vaccine for patients with chronic obstructive pulmonary disease. .
CrossRef93
Daniel Bautista, Bernardo Vila, Ruth Uso, Maria Tellez, Vicente Zanon. (2006) Predisposing, Reinforcing, and Enabling Factors Influencing Influenza Vaccination Acceptance Among Healthcare Workers • . Infection Control and Hospital Epidemiology 27:1, 73-77
CrossRef94
Abu H. Samad, Mohd H.B.H.J. Usul, Dalilah Zakaria, Raman Ismail, Anne Tasset-Tisseau, Florence Baron-Papillon, Alain Follet. (2006) Workplace Vaccination against Influenza in Malaysia: Does the Employer Benefit?. Journal of Occupational Health 48:1, 1-10
CrossRef95
Thomas R. Talbot, Suzanne F. Bradley, Sara E. Cosgrove, Christian Ruef, Jane D. Siegel, David J. Weber. (2005) Influenza Vaccination of Healthcare Workers and Vaccine Allocation for Healthcare Workers During Vaccine Shortages • . Infection Control and Hospital Epidemiology 26:11, 882-890
CrossRef96
Douglas K. Mitchell, Frederick L. Ruben, Stefan Gravenstein. (2005) IMMUNOGENICITY AND SAFETY OF INACTIVATED INFLUENZA VIRUS VACCINE IN YOUNG CHILDREN IN 2003???2004. The Pediatric Infectious Disease Journal 24:10, 925-927
CrossRef97
Karen Roush. (2005) Preventing Flu Outbreaks. AJN, American Journal of Nursing 105:10, 30-32
CrossRef98
Timothy M.E. Davis, Thilak Weerarathne, Yvonne Foong, Cliff Mason, Wendy A. Davis. (2005) Community-acquired infections in type 2 diabetic patients and their nondiabetic partners. Journal of Diabetes and its Complications 19:5, 259-263
CrossRef99
Terhi Tapiainen, Ulrich Heininger. (2005) Fever following immunization. Expert Review of Vaccines 4:3, 419-427
CrossRef100
K. L. Nichol, S. D. Heilly, E. Ehlinger. (2005) Colds and Influenza-Like Illnesses in University Students: Impact on Health, Academic and Work Performance, and Health Care Use. Clinical Infectious Diseases 40:9, 1263-1270
CrossRef101
Manuel W. Mah, Neil A. Hagen, Karen Pauling-Shepard, Joanne Standish Hawthorne, Marlene Mysak, Tara Lye, Thomas J. Louie. (2005) Understanding influenza vaccination attitudes at a Canadian cancer center. American Journal of Infection Control 33:4, 243-250
CrossRef102
R Thomas, T Jefferson, V Demicheli, Roger Thomas. 2005. Influenza vaccination for healthcare workers who work with the elderly. .
CrossRef103
Qiang Zhu, Haiyan Chang, Yan Chen, Fang Fang, Changyong Xue, Fenghua Zhang, Meizhen Qiu, Hanzhong Wang, Bin Wang, Ze Chen. (2005) Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice. Biochemical and Biophysical Research Communications 329:1, 87-94
CrossRef104
Andrew F. Shorr. (2005) Preventing Pneumonia: The Role for Pneumococcal and Influenza Vaccines. Clinics in Chest Medicine 26:1, 123-134
CrossRef105
Nancy A. Risebrough, Susan K. Bowles, Andrew E. Simor, Alison McGeer, Paul I. Oh. (2005) Economic Evaluation of Oseltamivir Phosphate for Postexposure Prophylaxis of Influenza in Long-Term Care Facilities. Journal of the American Geriatrics Society 53:3, 444-451
CrossRef106
Rainer Schmidt, Lothar Gierl. (2005) A prognostic model for temporal courses that combines temporal abstraction and case-based reasoning. International Journal of Medical Informatics 74:2-4, 307-315
CrossRef107
Ruth Kandel, Kevan L Hartshorn. (2005) Novel strategies for prevention and treatment of influenza. Expert Opinion on Therapeutic Targets 9:1, 1-22
CrossRef108
Mohammad Madjid, Imran Awan, Muzammil Ali, Lorraine Frazier, Ward Casscells. (2005) Influenza and atherosclerosis: vaccination for cardiovascular disease prevention. Expert Opinion on Biological Therapy 5:1, 91-96
CrossRef109
Larry D Lynd, Ron Goeree, Bernie J O???Brien. (2005) Antiviral Agents for Influenza. PharmacoEconomics 23:11, 1083-1106
CrossRef110
Lidia B. Brydak, Skwarczyński Tadeusz, Machaka Magdalena. (2004) Antibody Response to Influenza Vaccination in Healthy Adults. Viral Immunology 17:4, 609-615
CrossRef111
Cassandra D. Salgado, Eve T. Giannetta, Frederick G. Hayden, Barry M. Farr. (2004) Preventing Nosocomial Influenza by Improving the Vaccine Acceptance Rate of Clinicians • . Infection Control and Hospital Epidemiology 25:11, 923-928
CrossRef112
Barbara W. Trautner, Robert L. Atmar, Amy Hulstrom, Rabih O. Darouiche. (2004) Inactivated influenza vaccination for people with spinal cord injury. Archives of Physical Medicine and Rehabilitation 85:11, 1886-1889
CrossRef113
Sarah J. D’Heilly, Kristin L. Nichol. (2004) Work‐Site–Based Influenza Vaccination in Healthcare and Non‐Healthcare Settings • . Infection Control and Hospital Epidemiology 25:11, 941-945
CrossRef114
David B. Huang, Jashin J. Wu, Stephen K. Tyring. (2004) A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. Journal of Infection 49:3, 179-209
CrossRef115
P Villari, L Manzoli, A Boccia. (2004) Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine 22:25-26, 3475-3486
CrossRef116
Florence H.Y. Yap, Pak-Leung Ho, Kwok-Fai Lam, Paul K.S. Chan, Yeung-Hung Cheng, Joseph S.M. Peiris. (2004) Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. Journal of Medical Virology 73:4, 617-623
CrossRef117
V Demicheli, D Rivetti, JJ Deeks, TO Jefferson, Vittorio Demicheli. 2004. Vaccines for preventing influenza in healthy adults. .
CrossRef118
Alvaro Morales, Maria M. Martinez, Anne Tasset-Tisseau, Elena Rey, Florence Baron-Papillon, Alain Follet. (2004) Costs and Benefits of Influenza Vaccination and Work Productivity in a Colombian Company from the Employer's Perspective. Value in Health 7:4, 433-441
CrossRef119
Thomas D Szucs. (2004) Medical economics in the field of influenza—past, present and future. Virus Research 103:1-2, 25-30
CrossRef120
Kristin L Nichol, Paul Mendelman. (2004) Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Research 103:1-2, 3-8
CrossRef121
Paul V Targonski, Gregory A Poland. (2004) Intranasal Cold-Adapted Influenza Virus Vaccine Combined with Inactivated Influenza Virus Vaccines. Drugs & Aging 21:6, 349-359
CrossRef122
Yi-Hung Liu, Li-Min Huang, Jung-Der Wang. (2004) Reduction of Acute Respiratory Illness (ARI) due to a Voluntary Workplace Influenza Vaccination Program: Who are More Likely to Get the Benefit?. Journal of Occupational Health 46:6, 455-460
CrossRef123
Karl G Nicholson, John M Wood, Maria Zambon. (2003) Influenza. The Lancet 362:9397, 1733-1745
CrossRef124
Richard T. Lester, Allison McGeer, George Tomlinson, Allan S. Detsky. (2003) Use of, Effectiveness of, and Attitudes Regarding Influenza Vaccine Among House Staff • . Infection Control and Hospital Epidemiology 24:11, 839-844
CrossRef125
Naoki Kawai, Hideyuki Ikematsu, Norio Iwaki, Ietaka Satoh, Takashi Kawashima, Taizo Tsuchimoto, Seizaburo Kashiwagi. (2003) A prospective, Internet-based study of the effectiveness and safety of influenza vaccination in the 2001–2002 influenza season. Vaccine 21:31, 4507-4513
CrossRef126
NICOLA PRINCIPI, SUSANNA ESPOSITO, PAOLA MARCHISIO, ROBERTO GASPARINI, PIERO CROVARI. (2003) Socioeconomic impact of influenza on healthy children and their families. The Pediatric Infectious Disease JournalS207-S210
CrossRef127
Amal Nasir Mustafa, Bradford D. Gessner, Raman Ismail, Ahmad Faudzi Yusoff, Nasuruddin Abdullah, Ilina Ishak, Norazmi Abdullah, Mohd Ismail Merican. (2003) A case-control study of influenza vaccine effectiveness among Malaysian pilgrims attending the Haj in Saudi Arabia. International Journal of Infectious Diseases 7:3, 210-214
CrossRef128
Wayne N. Burton, Alan Morrison, Albert I. Wertheimer. (2003) Pharmaceuticals and Worker Productivity Loss: A Critical Review of the Literature. Journal of Occupational and Environmental Medicine 45:6, 610-621
CrossRef129
Michaël Schwarzinger, Karine Lacombe, Fabrice Carrat. (2003) Economic evaluations of neuraminidase inhibitors to control influenza. Expert Review of Pharmacoeconomics & Outcomes Research 3:2, 147-158
CrossRef130
Manabu Akazawa, Jody L. Sindelar, A. David Paltiel. (2003) Economic Costs of Influenza-Related Work Absenteeism. Value in Health 6:2, 107-115
CrossRef131
Ellen O'Brien. (2003) Employers' Benefits from Workers' Health Insurance. Milbank Quarterly 81:1, 5-43
CrossRef132
&NA;. (2003) Evidence points to influenza vaccination being cost-saving in healthy working adults. Drugs & Therapy Perspectives 19:3, 22-25
CrossRef133
L. E. Egede, D. Zheng. (2003) Racial/Ethnic Differences in Adult Vaccination Among Individuals With Diabetes. American Journal of Public Health 93:2, 324-329
CrossRef134
Letizia Toscani, Laurent Gauthey, Claude-François Robert. (2003) The information network of senior citizens in Geneva, Switzerland, and progress in flu vaccination coverage between 1991 and 2000. Vaccine 21:5-6, 393-398
CrossRef135
Micha??l Schwarzinger, Bruno Housset, Fabrice Carrat. (2003) Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults. PharmacoEconomics 21:3, 215-224
CrossRef136
J. Tooker. (2003) Affordable Health Insurance for All Is Possible by Means of a Pragmatic Approach. American Journal of Public Health 93:1, 106-109
CrossRef137
G. B. Byrnes. (2002) A Markov model for sample size calculation and inference in vaccine cost-effectiveness studies. Statistics in Medicine 21:21, 3249-3260
CrossRef138
Trish M. Perl. (2002) Why Are We Missing High-risk Patients?. Journal of General Internal Medicine 17:9, 736-737
CrossRef139
Gregory A. Poland. (2002) If You Could Halve the Mortality Rate, Would You Do It?. Clinical Infectious Diseases 35:4, 378-380
CrossRef140
Michael G Ison, John Mills, Peter Openshaw, Maria Zambon, Albert Osterhaus, Frederick Hayden. (2002) Current research on respiratory viral infections: Fourth International Symposium. Antiviral Research 55:2, 227-278
CrossRef141
Masayoshi Shinjoh, Takashi Yoshikawa, Yixing Li, Kyoko Shiraishi, Hideaki Ueki, Kuniaki Nerome. (2002) Prophylaxis and treatment of influenza encephalitis in an experimental mouse model. Journal of Medical Virology 67:3, 406-417
CrossRef142
Patti Ludwig-Beymer, Sharon Coghlan Gerc. (2002) An Influenza Prevention Campaign: The Employee Perspective. Journal of Nursing Care Quality 16:3, 1-12
CrossRef143
Elliot J. Coups, Gretchen B. Chapman. (2002) Formation and use of covariation assessments in the real world. Applied Cognitive Psychology 16:1, 51-71
CrossRef144
Maarten J. Postma, Paul Jansema, Marianne L.L. van Genugten, Marie-Louise A. Heijnen, Johannes C. Jager, Lolkje T.W. de Jong-van den Berg. (2002) Pharmacoeconomics of Influenza Vaccination for Healthy Working Adults. Drugs 62:7, 1013-1024
CrossRef145
Mario de Bernardi di Valserra, Alessandro Zanasi, Salvatore Ragusa, Reinhard Glück, Christian Herzog. (2002) An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clinical Therapeutics 24:1, 100-111
CrossRef146
Wilma Parlevliet, Corianne de Borgie, Gerard Frijstein, Henk-Jan Guchelaar. (2002) Cost-Benefit Analysis of Vaccination Against Influenza of Employees from an Academic Medical Centre. Disease Management & Health Outcomes 10:9, 579-587
CrossRef147
Roben Das Gupta, Julian F. Guest. (2002) A Model to Estimate the Cost Benefit of an Occupational Vaccination Programme for Influenza with Influvac?? in the UK*. PharmacoEconomics 20:7, 475-484
CrossRef148
Peter A. Muennig, Kamran Khan. (2001) Cost‐Effectiveness of Vaccination versus Treatment of Influenza in Healthy Adolescents and Adults. Clinical Infectious Diseases 33:11, 1879-1885
CrossRef149
The American Lung Association Asthma Clinical Research Centers. (2001) The Safety of Inactivated Influenza Vaccine in Adults and Children with Asthma. New England Journal of Medicine 345:21, 1529-1536
Full Text150
Ahmed, Faruque, Singleton, James A., Franks, Adele L., . (2001) Influenza Vaccination for Healthy Young Adults. New England Journal of Medicine 345:21, 1543-1547
Full Text151
J. A. Harraway, K. J. Sharples. (2001) A first course in biostatistics for health sciences students. International Journal of Mathematical Education in Science and Technology 32:6, 873-886
CrossRef152
Jenny A. Van Amburgh, Nancy M. Waite, Eric H. Hobson, Hedy Migden. (2001) Improved Influenza Vaccination Rates in a Rural Population as a Result of a Pharmacist-Managed Immunization Campaign. Pharmacotherapy 21:9, 1115-1122
CrossRef153
Margaret L. Russell, Cheryl A. Ferguson. (2001) Using Epidemiology to Target Staff Influenza Vaccination Programs • . Infection Control and Hospital Epidemiology 22:8, 525-526
CrossRef154
Sadir Alrawi, Iyad Houshan, Radhakrishnan Satheesan, Ramanathan Raju, Joseph Cunningham, Anthony Acinapura. (2001) Glove Reinforcement: An Alternative to Double Gloving • . Infection Control and Hospital Epidemiology 22:8, 526-527
CrossRef155
Gustavo H Dayan, Van Hung Nguyen, Roberto Debbag, Roberto Gómez, Susan C Wood. (2001) Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 19:30, 4204-4213
CrossRef156
Gregory A. Poland, Scott T. Rottinghaus, Robert M. Jacobson. (2001) Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 19:17-19, 2216-2220
CrossRef157
Alexander Kiderman, Arthur Furst, Brendon Stewart, Evegenia Greenbaum, Avraham Morag, Zichria Zakay-Rones. (2001) A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997–98. Journal of Clinical Virology 20:3, 155-161
CrossRef158
Robert J. McCunney. (2001) Health and Productivity: A Role for Occupational Health Professionals. Journal of Occupational and Environmental Medicine 43:1, 30-35
CrossRef159
Ruth Kandel, Kevan L. Hartshorn. (2001) Prophylaxis and Treatment of Influenza Virus Infection. BioDrugs 15:5, 303-323
CrossRef160
Martin Ehlers, Chris Silagy, Douglas Fleming, Daryl Freeman. (2001) New Approaches for Managing Influenza in Primary Care. Clinical Drug Investigation 21:6, 443-452
CrossRef161
Peter Cram, Susan G. Blitz, Arnold Monto, A. Mark Fendrick. (2001) Influenza. PharmacoEconomics 19:3, 223-230
CrossRef162
J Gaillat. (2001) Que penser du traitement antiviral de la grippeen l’an 2001 ?. La Revue de Médecine Interne 22:1, 53-61
CrossRef163
Wood, Alastair J.J., , Couch, Robert B., . (2000) Prevention and Treatment of Influenza. New England Journal of Medicine 343:24, 1778-1787
Full Text164
JOSEPH J. MARTOCCHIO, DAVID A. HARRISON, HOWARD BERKSON. (2000) CONNECTIONS BETWEEN LOWER BACK PAIN, INTERVENTIONS, AND ABSENCE FROM WORK: A TIME-BASED META-ANALYSIS. Personnel Psychology 53:3, 595-624
CrossRef165
Susan C. Wood, Van Hung Nguyen, Claudia Schmidt. (2000) Economic Evaluations of Influenza Vaccination in Healthy Working-Age Adults. PharmacoEconomics 18:2, 173-183
CrossRef166
PJ Poole, E Chacko, RWB Wood-Baker, CJ Cates, Phillippa Poole. 2000. Influenza vaccine for patients with chronic obstructive pulmonary disease. .
CrossRef167
Lidia B. Brydak, Magdalena Machala. (2000) Humoral Immune Response to Influenza Vaccination in Patients from High Risk Groups. Drugs 60:1, 35-53
CrossRef168
Huma Qureshi, Bradford D Gessner, Didier Leboulleux, Habiba Hasan, Syed Ejaz Alam, Lawrence H Moulton. (2000) The incidence of vaccine preventable influenza-like illness and medication use among Pakistani pilgrims to the Haj in Saudi Arabia
This study was funded in part by Aventis Pasteur (formerly Pasteur Mérieux Connaught), a producer of influenza vaccine.. Vaccine 18:26, 2956-2962
CrossRef169
Catherine E. Ammon. (2000) A survey of institutional influenza vaccination in Switzerland. Sozial- und Pr
ventivmedizin SPM 45:4, 182-187
CrossRef170
Kathleen M. Neuzil. (2000) Influenza: New insights into an old disease. Current Infectious Disease Reports 2:3, 224-230
CrossRef171
T.G. Boyce, G.A. Poland. (2000) Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomedicine & Pharmacotherapy 54:4, 210-218
CrossRef172
Arnold S. Monto, A. Mark Fendrick. (2000) Developments in Influenza Prevention and Treatment. Disease Management and Health Outcomes 7:5, 235-243
CrossRef173
C. Walls. (2000) Reasons That Healthcare Workers Decline Influenza Vaccination in a New Zealand Hospital Environment • . Infection Control and Hospital Epidemiology 21:4, 249-250
CrossRef174
E. A. Bryce, K. Dorovoni‐Zis, D. Trudeau, M. Sinclair, F. J. Roberts. (2000) Creutzfeldt‐Jakob Disease: Management of Accidental Contamination of Neurosurgical Instruments, Pathology Equipment, and Solutions • . Infection Control and Hospital Epidemiology 21:4, 247-248
CrossRef175
C. Webster, K. J. Towner, H. Humphreys. (2000) Survival of Acinetobacter on Three Clinically Related Inanimate Surfaces • . Infection Control and Hospital Epidemiology 21:4, 246-246
CrossRef176
Smita Halder, Leroy Benons, Paola Dey, Ciaran Woodman, Kevin Snee. (2000) Nosocomial influenza infection. The Lancet 355:9210, 1187-1188
CrossRef177
J. H. Wagenvoort, H. M. Toenbreker, T. J. Werink, H. H. Berendsen. (2000) Once MRSA, Always MRSA? Setting Up a Hospital Preadmission Questionnaire • . Infection Control and Hospital Epidemiology 21:4, 251-252
CrossRef178
C. C. Cardoso, J. E. Fiorini, L. R. Ferriera, J. W. Gurjao, L. A. Amaral. (2000) Disinfection of Hospital Laundry Using Ozone: Microbiological Evaluation • . Infection Control and Hospital Epidemiology 21:4, 248-248
CrossRef179
A. E. Macias. (2000) Impact of Nosocomial Infections on Outcome: Myths and Evidence • . Infection Control and Hospital Epidemiology 21:4, 248-249
CrossRef180
R. O. Suara, M. Young, I. Reeves. (2000) Risk Factors for Nosocomial Infection in a High‐Risk Nursery • . Infection Control and Hospital Epidemiology 21:4, 250-251
CrossRef181
Atul K. Kapur, Milton Tenenbein. (2000) Vaccination of Emergency Department Patients at High Risk for Influenza. Academic Emergency Medicine 7:4, 354-358
CrossRef182
Daniel Stamboulian, Pablo E. Bonvehí, Francisco M. Nacinovich, Nancy Cox. (2000) INFLUENZA. Infectious Disease Clinics of North America 14:1, 141-166
CrossRef183
Jim E. Eyles, E. Diane Williamson, H. Oya Alpar. (2000) Intranasal Administration of Influenza Vaccines. BioDrugs 13:1, 35-59
CrossRef184
A.D.M.E Osterhaus, J.C de Jong. (1999) The control of influenza: antivirals as an adjunct to vaccines. Vaccine 18:9-10, 779-780
CrossRef185
R Valdez, K M Narayan, L S Geiss, M M Engelgau. (1999) Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults.. American Journal of Public Health 89:11, 1715-1721
CrossRef186
René Snacken. (1999) Control of influenza. Public health policies. Vaccine 17, S61-S63
CrossRef187
Susan C Wood, Alexeı̈ Alexseiv, Van Hung Nguyen. (1999) Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 17, S81-S87
CrossRef188
Wayne N. Burton, Daniel J. Conti, Chin-Yu Chen, Alyssa B. Schultz, Dee W. Edington. (1999) The Role of Health Risk Factors and Disease on Worker Productivity. Journal of Occupational & Environmental Medicine 41:10, 863-877
CrossRef189
Nancy J Cox, Kanta Subbarao. (1999) Influenza. The Lancet 354:9186, 1277-1282
CrossRef190
Carol M. Mason, Steve Nelson. (1999) PULMONARY HOST DEFENSES. Clinics in Chest Medicine 20:3, 475-488
CrossRef191
HARRI SAXÉN, MARTTI VIRTANEN. (1999) Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. The Pediatric Infectious Disease Journal 18:9, 779-783
CrossRef192
Kristin L Nichol. (1999) Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults. Vaccine 17, S67-S73
CrossRef193
Lone Simonsen. (1999) The global impact of influenza on morbidity and mortality. Vaccine 17, S3-S10
CrossRef194
Mark A Miller. (1999) Considerations for adding pneumonia and influenza vaccines to public health programmes. Vaccine 17, S95-S98
CrossRef195
Jean Burris, Geary W. Olsen, Michele M. Burlew, Marianne E. Steinberg, John A. Stoltzfus, Jeffrey H. Mandel. (1999) Workplace Influenza Immunization Update. Journal of Occupational & Environmental Medicine 41:6, 415
CrossRef196
Peter A Gross, Steven J Sperber, Armen Donabedian, Sandy Dran, Gail Morchel, Patricia Cataruozolo, Gary Munk. (1999) Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Vaccine 17:18, 2284-2289
CrossRef197
Nora G. Singer, W. Joseph McCune. (1999) Prevention of infectious complications in rheumatic disease patients. Current Opinion in Rheumatology 11:3, 173-178
CrossRef198
Robert F. Breiman, Jay C. Butler, Pamela M. McInnes. (1999) Vaccines to prevent respiratory infection: opportunities on the near and far horizon. Current Opinion in Infectious Diseases 12:2, 145-152
CrossRef199
John Mullahy. (1999) It'll only hurt a second? Microeconomic determinants of who gets flu shots. Health Economics 8:1, 9-24
CrossRef200
John S Oxford, Robert Lambkin. (1998) Targeting influenza virus neuraminidase—a new strategy for antiviral therapy. Drug Discovery Today 3:10, 448-456
CrossRef201
Ann M. Baker, Bruce McCarthy, Virginia F. Gurley, Marianne Ulcickas Yood. (1998) Influenza Immunization in a Managed Care Organization. Journal of General Internal Medicine 13:7, 469-475
CrossRef202
Leighton Chan, Peter M. Houck, Roger A. Rosenblatt, Gary Hart, Laura-Mae Baldwin. (1998) Influenza vaccinations of Washington State Medicare beneficiaries seen by physiatrists in the outpatient setting in 1994. Archives of Physical Medicine and Rehabilitation 79:6, 599-603
CrossRef203
Barnett, Elizabeth D., . (1998) Influenza Immunization for Children. New England Journal of Medicine 338:20, 1459-1461
Full Text204
Geary W. Olsen, Jean M. Burris, Michele M. Burlew, Marianne E. Steinberg, Nancy V. Patz, John A. Stoltzfus, Jeffrey H. Mandel. (1998) Absenteeism Among Employees Who Participated in a Workplace Influenza Immunization Program. Journal of Occupational & Environmental Medicine 40:4, 311-316
CrossRef205
William E. Scheckler, Dennis Brimhall, Alfred S. Buck, Barry M. Farr, Candace Friedman, Richard A. Garibaldi, Peter A. Gross, Jo-Ann Harris, Walter J. Hierholzer, William J. Martone, Linda L. McDonald, Steven L. Solomon. (1998) Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: A Consensus Panel report. American Journal of Infection Control 26:1, 47-60
CrossRef206
David S. Fedson, Yoshio Hirota, Hak-Kyoon Shin, Pierre-Etienne Cambillard, James Kiely, Franz Ambrosch, Claude Hannoun, Jane Leese, Marc J.W. Sprenger, Alan W. Hampson, Klaus Bro-Jørgensen, Ann-Marie Ahlbom, Hanne Nøkleby, Martti Valle, Olafur Olafsson, Francisco Salmerón, Jann Cloetta, Helena Rebelo de Andrade, René Snacken, Isabella Donatelli, Lance C. Jennings, Raymond A. Strikas. (1997) Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 15:14, 1506-1511
CrossRef207
Martin E. Evans, Kathleen L. Hall, Sharon E. Berry. (1997) Influenza control in acute care hospitals. American Journal of Infection Control 25:4, 357-362
CrossRef208
Wendy A. Keitel, Thomas R. Cate, Robert B. Couch, Linda L. Huggins, Kenneth R. Hess. (1997) Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 15:10, 1114-1122
CrossRef209
Roger D. Yusen, Stephen S. Lefrak, Elbert P. Trulock. (1997) EVALUATION AND PREOPERATIVE MANAGEMENT OF LUNG VOLUME REDUCTION SURGERY CANDIDATES. Clinics in Chest Medicine 18:2, 199-224
CrossRef210
Douglas S. Campbell, Maria H. Rumley. (1997) Cost-Effectiveness of the Influenza Vaccine in a Healthy, Working-Age Population. Journal of Occupational & Environmental Medicine 39:5, 408-414
CrossRef211
Laurent Gauthey, Letizia Toscani, Jean-Claude Schira. (1997) Vaccination contre la grippe en Suisse. Sozial- und Pr
CrossRef212
Reinhard Gl
CrossRef213
Bradley N. Doebbeling, Michael B. Edmond, Charles S. Davis, James R. Woodin, Rodney R. Zeitler. (1997) Influenza Vaccination of Health Care Workers: Evaluation of Factors That Are Important in Acceptance. Preventive Medicine 26:1, 68-77
CrossRef214
John V. L. Sheffield, Eric B. Larson. (1996) General internal medicine update. Journal of General Internal Medicine 11:10, 613-621
CrossRef215
(1996) Vaccination against Influenza in Healthy Adults. New England Journal of Medicine 334:6, 402-404
Full Text216
Patriarca, Peter A., , Strikas, Raymond A., . (1995) Influenza Vaccine for Healthy Adults?. New England Journal of Medicine 333:14, 933-934
Full Text
- Letters
